CAS: 114562-59-3; (+/-)-N-Hydroxy-3 4-Methylenedioxyamphe&

专利信息

专利号:US-11717498-B2
优先权日:2013-12-31
标题 :Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms
发明人：POPP KARL; MECKLER HAROLD
权利人:Chemapotheca LLC; PHARMAPOTHECA A INC
摘要:The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

专利号:US-12208068-B2
优先权日:2013-12-31
标题:Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
发明人：POPP KARL; MECKLER HAROLD
权利人:PHARMAPOTHECA A INC
摘要:The invention also relates to processes for producing abuse deterrent pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

专利号:US-2025213502-A1
优先权日:2016-02-24
标 题 :Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms
发明人：POPP KARL; MECKLER HAROLD
权利人:PHARMAPOTHECA A INC
摘要:The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.